drugset / Trial / NCT03404648

Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

NCT03404648

Phase 3 Completed 19 enrolled Mayo Clinic
NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to find out if a PET/MR scan in combination with standard MRI and CT scans can improve the early detection and treatment of patients with prostate cancer.

Timeline

Start
2017-11-01
Primary completion
2020-01-23
Completion
2020-01-23

Drugs

EvaluationDrugModalityDoseRoute
Subject C-11 choline PET tracer Diagnostic / imaging agent 444 mbq Intravenous
Subject C-11 choline PET tracer Diagnostic / imaging agent 518 mbq Intravenous
Background Gadobutrol Diagnostic / imaging agent 0.1 unknown Intravenous